ArticleNature communications2025
Impact and cost-effectiveness of the community-led AMETHIST intervention among female sex workers in Zimbabwe.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Female sex workers (FSW) face high HIV risk of HIV transmission and acquisition. The AMETHIST ("Adapted Microplanning: Eliminating Transmissible HIV In Sex Transactions") trial enhanced Zimbabwe's Key Populations (KP) programme by providing targeted, community-based support for FSW. We used the HIV Synthesis Model to assess its long-term impact and cost-effectiveness. Given USAID's major role in funding, we also evaluated the effects of ending US support on the KP programme. We modelled a KP programme from 2010. From 2024 we compared (i) continuation of KP programme to (ii) continuation of KP programme + 'AMETHIST' intervention. We assessed HIV outcomes in 2030 and conducted cost-effectiveness analysis over a 50 year time horizon. Similar analyses were undertaken comparing continuation of the current KP programme to discontinuation. Here we show that AMETHIST had greater positive impact than the KP programme alone; a higher proportion of FSW tested for HIV in the past year, were diagnosed, on ART and had undetectable viral loads compared to the KP programme alone. Disability adjusted life years were averted with AMETHIST and it was cost-saving within 15 years. Continuing the current KP programme was also cost-saving compared to discontinuation of the KP programme.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.